| GlaxoSmithKline AG - Trelegy Ellipta, Einzeldosiertes Pulver zur Inhalation |
| 66808 | | 01 | | Trelegy Ellipta | | Einzeldosiertes Pulver zur Inhalation | | R03AL08 | | Vilanterol, Umeclidinium Bromide and Fluticasone Furoate | | 20.09.2018 | | |
|
| Composition |
| fluticasoni furoas 100 µg, umeclidinium 62.5 µg ut umeclidinii bromidum, vilanterolum 25 µg ut vilanteroli trifenatas, excipiens ad pulverem pro dosi. |
| Packungsbestandteile |
| Einzeldosiertes Pulver zur Inhalation | | | | | | | | Principe actif | Concentr. |
|---|
| Fluticasoni Furoas | 100 µg | | Umeclidinium | 62.5 µg | | Vilanterolum | 25 µg |
| | BAG: Principe actif | Concentr. |
|---|
| Fluticasoni Furoas | 92 mcg | | Umeclidinium | 55 mcg | | Vilanterolum | 22 mcg |
|
|
|
